Objective:

To evaluate the efficacy and safety of recombinant human brain natriuretic peptide (rhBNP) for treating sepsis complicated by heart failure (SCHF), highlighting its potential as a novel therapeutic approach in light of existing treatments.

Key Findings:

• rhBNP may reduce 28-day mortality and protect cardiac function in some studies, suggesting potential benefits in specific patient populations.
• Other studies report no significant survival improvement with rhBNP, indicating the need for careful patient selection.
• Elevated BNP/NT-proBNP levels correlate with sepsis severity and myocardial dysfunction, reinforcing their role as biomarkers.

Interpretation:

The clinical efficacy of rhBNP in treating SCHF remains controversial, with mixed results regarding its impact on mortality and cardiac function, necessitating further investigation into its clinical application.

Limitations:

• Inclusion of only RCTs may limit generalizability, as real-world effectiveness may differ.
• Variability in study designs and patient populations could affect outcomes, introducing potential biases.

Conclusion:

Further research is needed to clarify the role of rhBNP in SCHF treatment, as current evidence presents conflicting results; future studies should focus on specific patient demographics and treatment protocols.